DR. LEE JAY HELMAN, MD
Osteopathic Medicine at Shadywood Rd, Bethesda, MD
License number
Maryland D25357
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
7600 Shadywood Rd, Bethesda, MD 20817
Phone
(301) 299-2922
Personal information
See more information about LEE JAY HELMAN at radaris.comName
Address
Phone
7600 Shadywood Rd, Bethesda, MD 20817
Bethesda, MD
7600 Shadywood Rd, Bethesda, MD 20817
Organization information
See more information about LEE JAY HELMAN at bizstanding.comLee Jay Helman MD
7600 Shadywood Rd, Bethesda, MD 20817
Industry:
Medical Doctor's Office, Nonclassifiable Establishments
Medical Doctor:
Lee J. Helman (Medical Doctor)
Professional information
See more information about LEE JAY HELMAN at trustoria.com
Dr. Lee J Helman, Bethesda MD - MD (Doctor of Medicine)
Dr. Lee J Helman, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
9000 Rockville Pike SUITE 31A, Bethesda 20892
(301) 496-4257 (Phone), (301) 402-0575 (Fax)
CENTER FOR CANCER RESEARCH
31 Ctr Dr, Bethesda 20892
(301) 496-4257 (Phone), (301) 496-0775 (Fax)
(301) 496-4257 (Phone), (301) 402-0575 (Fax)
CENTER FOR CANCER RESEARCH
31 Ctr Dr, Bethesda 20892
(301) 496-4257 (Phone), (301) 496-0775 (Fax)
Certifications:
Internal Medicine, 1983, Medical Oncology, 1985
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Maryland At Baltimore / Professional Schools
Graduated: 1980
Barnes-Jewish Hospital
National Institutes Of Health Clinical Center
University of Maryland At Baltimore / Professional Schools
Graduated: 1980
Barnes-Jewish Hospital
National Institutes Of Health Clinical Center
Peptides Containing A Fusion Joint Of A Chimeric Protein Encoded By Dna Spanning A Tumor-Associated Chromosomal Translocation And Their Use As Immunogens
Peptides Containing A Fusion Joint Of A Chimeric Protein Encoded By Dna Spanning A Tumor-Associated Chromosomal Translocation And Their Use As Immunogens
US Patent:
5997869, Dec 7, 1999
Filed:
Sep 14, 1995
Appl. No.:
8/528129
Inventors:
Theresa J. Goletz - Kensington MD
Jay A. Berzofsky - Bethesda MD
Lee J. Helman - Bethesda MD
Jay A. Berzofsky - Bethesda MD
Lee J. Helman - Bethesda MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
A61K 3900, A61K 3800, A61K 3804
US Classification:
4241841
Abstract:
A method of immunizing a mammal against a tumor cell by exposing splenic or peripheral blood mononuclear cells to a peptide that encompasses a fusion joint of a fusion protein encoded by DNA spanning a human chromosomal translocation associated with Ewing's sarcoma (t(11;22)(q24;q12)) or alveolar rhabdomyosarcoma (t(2:13)(q35;q14)) is provided.
Novel Anti-Igf-Ir Antibodies And Uses Thereof
Novel Anti-Igf-Ir Antibodies And Uses Thereof
US Patent:
2013027, Oct 17, 2013
Filed:
Feb 26, 2013
Appl. No.:
13/777040
Inventors:
- Toulouse, FR
OLIVIER LEGER - Boulogne-Billancourt, FR
NELLY KUKLIN - Boston MA, US
MICHAEL CHASTAIN - Seattle WA, US
DAVID G. BROOKS - Concord MA, US
LEE J. HELMAN - BETHESDA MD, US
OLIVIER LEGER - Boulogne-Billancourt, FR
NELLY KUKLIN - Boston MA, US
MICHAEL CHASTAIN - Seattle WA, US
DAVID G. BROOKS - Concord MA, US
LEE J. HELMAN - BETHESDA MD, US
International Classification:
C07K 16/22
US Classification:
4241331, 4241581, 4241451
Abstract:
The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
Immunogenic Peptides And Methods Of Use For Treating And Preventing Cancer
Immunogenic Peptides And Methods Of Use For Treating And Preventing Cancer
US Patent:
7867977, Jan 11, 2011
Filed:
Oct 24, 2006
Appl. No.:
12/092449
Inventors:
Jay A. Berzofsky - Bethesda MD, US
Leon T. Van Den Broeke - Zoutelande, NL
Crystal MacKall - Silver Spring MD, US
Lee J. Helman - Bethesda MD, US
Leon T. Van Den Broeke - Zoutelande, NL
Crystal MacKall - Silver Spring MD, US
Lee J. Helman - Bethesda MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 38/00
US Classification:
514 15, 514 16, 530328
Abstract:
Disclosed are immunogenic peptides, related fusion proteins, nucleic acids encoding the peptides or fusion proteins, conjugates, expression vectors, host cells, and antibodies. Also, disclosed are pharmaceutical compositions, vaccines for use in the treatment or prevention of cancer, e. g. , alveolar rhabodomyosarcoma, methods of stimulating a T cell to kill a tumor cell, methods of stimulating CD4 and CD8 T cells, and methods of treating or preventing cancer are further provided herein.
Immunogenic Peptides And Methods Of Use For Treating And Preventing Cancer
Immunogenic Peptides And Methods Of Use For Treating And Preventing Cancer
US Patent:
8614304, Dec 24, 2013
Filed:
Dec 13, 2010
Appl. No.:
12/966341
Inventors:
Jay A. Berzofsky - Bethesda MD, US
Leon T. Van den Broeke - Zoutelande, NL
Crystal Mackall - Silver Spring MD, US
Lee J. Helman - Bethesda MD, US
Leon T. Van den Broeke - Zoutelande, NL
Crystal Mackall - Silver Spring MD, US
Lee J. Helman - Bethesda MD, US
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Serives - Washington DC
International Classification:
C07H 21/02
US Classification:
536 231, 514 44 R
Abstract:
Disclosed are immunogenic peptides, related fusion proteins, nucleic acids encoding the peptides or fusion proteins, conjugates, expression vectors, host cells, and antibodies. Also, disclosed are pharmaceutical compositions, vaccines for use in the treatment or prevention of cancer, e. g. , alveolar rhabodomyosarcoma, methods of stimulating a T cell to kill a tumor cell, methods of stimulating CD4 and CD8 T cells, and methods of treating or preventing cancer are further provided herein.